|
|
|
| Effect of Tofacitinib on Peripheral Lymphocyte Subpopulations in Patients with Rheumatoid Arthritis Complicated with Interstitial Lung Disease |
| WANG Yuanyuan, YANG Haiyang, CAO Juan |
| Department of Laboratory,Luohe Central Hospital,Luohe Henan 462000 |
|
|
|
|
Abstract 【Objective】To explore the clinical efficacy of tofacitinib in the treatment of patients with rheumatoid arthritis (RA) complicated with interstitial lung disease (ILD) and its influence on peripheral lymphocyte subsets of these patients. 【Methods】A total of 120 patients with RA complicated with ILD diagnosed and treated in our hospital from March 2020 to March 2023 were selected and divided into the control group (treated with methylprednisolone tablets) and the observation group (treated with tofacitinib combined with methylprednisolone tablets) according to different treatment regimens, with 60 cases in each group. Improvement of clinical symptoms (morning stiffness of the joints, joint swelling and joint pain), laboratory indicators, pulmonary function indicators and peripheral lymphocyte subsets were compared between the two groups. 【Results】After the treatment, the improvement of clinical symptoms in the observation group was better than those in the control group. After treatment, the levels of tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), D-dimer (D-D), rheumatoid factor (RF), and salivary liquid sugar chain antigen (KL-6) in the observation group were significantly lower than those in the control group. After treatment, the vital capacity (VC), total lung capacity (TLC), forced vital capacity (FVC), and the lung's diffusion capacity for carbon monoxide (DLCO) in the observation group were significantly higher than those in the control group. After treatment, CD4+ and CD4+/CD8+ in both groups significantly increased, while CD8+ significantly decreased. Moreover, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while CD8+ was lower than that in the control group. The differences were statistically significant (P<0.05). 【Conclusion】Tofacitinib in the treatment of patients with RA complicated with ILD can effectively improve the clinical symptoms, laboratory indicators and pulmonary function indicators of patients, and enhance the immune function.
|
|
Received: 26 June 2024
|
|
|
|
|
|
[1] 冯钰玲,张天悦,冯馨仪,等. 类风湿关节炎相关间质性肺病危险因素及疾病进展的高分辨率CT研究[J].实用放射学杂志,2023,39(4):539-543.
[2] 王聪颖,韩蕊,李晶芳,等. 类风湿关节炎相关间质性肺病发病机制、诊断及治疗研究进展[J].天津中医药大学学报,2022,41(2):250-257.
[3] 耿魁魁,史天陆,沈爱宗,等. 新型生物和靶向制剂治疗难治性类风湿关节炎的研究进展[J].中国药房,2021,32(22):2807-2813.
[4] 王慧杰,秦蕾,夏光涛. 托法替布治疗间质性肺疾病的研究进展[J].世界临床药物,2021,42(4):308-313.
[5] 孟利花,谢戬芳,段培青,等. 类风湿关节炎合并间质性肺疾病患者外周淋巴细胞亚群失衡特点分析[J].山西医科大学学报,2022,53(7):892-897.
[6] ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [J].Ann Rheum Dis,2010,69(9):1580-1588.
[7] RAGHU G, REMY-JARDIN M, RICHELDI L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline[J].Am J Respir Crit Care Med,2022,205(9):e18-e47.
[8] 于晶晶,李慧敏,马瑞瑞,等. 类风湿关节炎合并骨质疏松的发病机制和治疗进展[J].中国现代医学杂志,2020,30(24):51-56.
[9] 丁志兰,肖堂琴. 情绪宣泄坊团体干预模式在间质性肺病合并心境障碍患者中的应用价值[J].医学临床研究,2023,40(3):450-452.
[10] 谢文慧,张卓莉. 类风湿关节炎药物治疗新进展[J].中国临床药理学杂志,2023,39(14):2111-2115.
[11] 邹雪,张丽卿. Janus激酶抑制剂及其在类风湿关节炎治疗中的作用研究进展[J].山东医药,2022,62(31):107-110.
[12] 李晟,刘雪梅,吕文浩. 鹿瓜多肽注射液治疗膝关节骨性关节炎患者的疗效[J].医学临床研究,2022,39(9):1402-1405.
[13] 赵金英,吴小芬,杜军,等. 硫酸羟氯喹治疗老年类风湿关节炎的疗效及对患者炎症、自身抗体的影响[J].海军医学杂志,2020,41(6):699-703.
[14] 李舒,万磊,刘健,等. 雷公藤多苷片对类风湿关节炎合并间质性肺病患者的临床疗效[J].中成药,2023,45(9):2896-2901.
[15] 谢阿青,吴晓燕,李红胜. 外周血淋巴细胞亚群在类风湿关节炎诊断中的应用[J].中国卫生检验杂志,2022,32(15):1875-1878. |
|
|
|
2025, Vol. 42 
